{
  "date": "2026-02-03",
  "items": [
    {
      "id": "1",
      "headline": "Amarin v. Hikma: settling the skinny label question",
      "preview": "The Supreme Court is set to review a case on generic drug marketing practices.",
      "article": "The U.S. Supreme Court is hearing Hikma Pharmaceuticals v. Amarin Pharma, a case concerning the marketing of a generic drug with a 'skinny label.' This dispute raises questions about patent infringement and how generics can market products without promoting off-label uses.\n\nAmarin's Vascepa was initially approved for high triglyceride levels, later receiving a separate approval for cardiovascular events. Hikma's generic version was approved with a skinny label, leading to Amarin's claims that Hikma's marketing could induce infringement of Amarin's patents. The Supreme Court's decision will clarify the boundaries of regulatory compliance and its implications for generic drug marketing.\n\nWhy this matters: The outcome could significantly impact how generics approach marketing and the protection of secondary patents, influencing both innovation and competition in the pharmaceutical industry.",
      "sources": [
        {
          "name": "Labiotech.eu",
          "url": "https://www.labiotech.eu/in-depth/amarin-hikma-skinny-label/",
          "type": "news",
          "verified_date": "2026-02-02"
        }
      ]
    },
    {
      "id": "2",
      "headline": "Kahimmune launches and secures exclusive license for dark-genome cancer vaccine platform",
      "preview": "Kahimmune Therapeutics has launched with a focus on dark-genome cancer vaccines.",
      "article": "Kahimmune Therapeutics has secured an exclusive licensing agreement for a technology platform that identifies tumor antigens from the non-coding genome. The company aims to develop shared mRNA cancer vaccines, starting with programs targeting colorectal and pancreatic cancer.\n\nThe licensed technology, derived from research at Gustave Roussy, focuses on immunogenic peptides from non-coding regions of the genome. Kahimmune plans to raise \u20ac8 million in seed funding to support its development efforts. This innovative approach could enhance cancer vaccine efficacy by targeting therapy-specific neoantigens.\n\nWhy this matters: By exploring the dark genome, Kahimmune may unlock new avenues for cancer treatment, potentially leading to more effective vaccines and improved patient outcomes.",
      "sources": [
        {
          "name": "European Biotechnology Magazine",
          "url": "https://european-biotechnology.com/latest-news/kahimmune-launch-dark-genome-cancer-vaccine-biotech/",
          "type": "news",
          "verified_date": "2026-02-02"
        }
      ]
    },
    {
      "id": "3",
      "headline": "Epimutations driven by RNAi or heterochromatin evoke transient antimicrobial drug resistance in pathogenic Mucor fungi",
      "preview": "Research reveals how Mucor fungi develop transient resistance to antifungal drugs.",
      "article": "A study published in PLOS Biology investigates how Mucor fungi adapt to antifungal treatments, particularly FK506. The research found that most FK506-resistant isolates were transiently resistant, reverting to sensitivity when not exposed to the drug.\n\nThe study identified two main mechanisms of resistance: RNAi-dependent epimutation and heterochromatin-mediated silencing. These findings highlight the complex strategies fungi use to adapt to antifungal pressures, which could inform future treatment approaches.\n\nWhy this matters: Understanding these resistance mechanisms is crucial for developing effective antifungal therapies and addressing the growing threat of antimicrobial resistance.",
      "sources": [
        {
          "name": "PLOS Biology",
          "url": "https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003598",
          "type": "paper",
          "verified_date": "2026-02-02"
        }
      ]
    },
    {
      "id": "4",
      "headline": "STAT+: FDA officials push for long-term monitoring of autoimmune patients receiving CAR-T therapy",
      "preview": "FDA officials recommend long-term studies for CAR-T therapy in autoimmune conditions.",
      "article": "FDA officials have called for long-term monitoring of patients receiving CAR-T therapy for autoimmune diseases, citing potential risks such as cancer and fertility issues. The recommendations were published in an op-ed in the Annals of Internal Medicine.\n\nWhile the specific duration for monitoring autoimmune patients is not defined, the FDA typically requires 15 years of follow-up for cancer patients treated with CAR-T. This push for long-term studies underscores the need for thorough safety evaluations in new therapeutic applications.\n\nWhy this matters: Ensuring the safety of CAR-T therapies in autoimmune patients is critical for patient health and the credibility of these advanced treatments.",
      "sources": [
        {
          "name": "STAT Biotech news: Market-moving coverage of drug development",
          "url": "https://www.statnews.com/2026/02/02/fda-long-term-follow-up-studies-car-t-therapy-automimmune-disorders/?utm_campaign=rss",
          "type": "news",
          "verified_date": "2026-02-02"
        }
      ]
    },
    {
      "id": "5",
      "headline": "BIO tells Congress how to maintain US biotech leadership",
      "preview": "BIO outlines strategies for Congress to support the U.S. biotech industry.",
      "article": "The Biotechnology Innovation Organization (BIO) has presented strategies to Congress aimed at maintaining U.S. leadership in biotechnology. In a recent statement, BIO emphasized the industry's growth and its importance to public health and the economy.\n\nKey recommendations include enhancing the business environment for biotech startups, supporting U.S. manufacturing, and fostering workforce development. BIO also advocates for international trade cooperation to expand market access for biotech products.\n\nWhy this matters: Strengthening the biotech sector is essential for innovation, job creation, and ensuring access to advanced medical treatments for Americans.",
      "sources": [
        {
          "name": "Bio.News",
          "url": "https://bio.news/health/bio-tells-congress-how-to-maintain-us-biotech-leadership/",
          "type": "news",
          "verified_date": "2026-02-02"
        }
      ]
    }
  ]
}